Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.32 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.32 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.32 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.32 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.32 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.32 |
| ▸ | BMPR2 | Q13873 | 2/20 | 0.32 |
| ▸ | CLK2 | P49760 | 5/20 | 0.31 |
| ▸ | HIPK1 | Q86Z02 | 5/20 | 0.31 |
| ▸ | HIPK2 | Q9H2X6 | 5/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.31 |
| ▸ | HIPK3 | Q9H422 | 4/20 | 0.31 |
| ▸ | CLK1 | P49759 | 3/20 | 0.31 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1330672 | 0.73 | DGAT1 (0.38) | DGAT1ROCK2 | |
| SCHEMBL5248323 | 0.71 | MAPT (0.41) | KDR | |
| SCHEMBL29300737 | 0.71 | DGAT1 (0.41) | DGAT1 | |
| SCHEMBL4810703 | 0.70 | DGAT1 (0.42) | DGAT1KDR | |
| SCHEMBL26102188 | 0.69 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL15401348 | 0.69 | PIM1 (0.39) | DGAT1CLK2HIPK1HIPK2CLK4 | |
| SCHEMBL3513153 | 0.69 | CYP19A1 (0.41) | DGAT1 | |
| SCHEMBL1440942 | 0.69 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL30385717 | 0.68 | KMO (0.48) | DGAT1 | |
| SCHEMBL2318217 | 0.68 | KMO (0.48) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066350-A1 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2025-02-27 | — | — | US | disclosed |
| CN-116262749-A | Aromatic heterocycle substituted compound and preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066350-A1 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ATR, WEE1, WEE2 | DGAT1 4049/4885KDR 2111/4885PRKAB1 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.